© 1995 American Heart Association, Inc.
Articles |
Pravastatin Modulates Cholesteryl Ester Transfer From HDL to ApoB-Containing Lipoproteins and Lipoprotein Subspecies Profile in Familial Hypercholesterolemia
From the Institut National de la Santé et de la Recherche Médicale, Unité 321, Pavillon Benjamin Delessert, Hôpital de la Pitié (M.G., M.J.C.), Rhône-Poulenc Rorer, Division Spécia, Paris (J.G.), Laboratoire du Métabolisme des Lipides, Institut National de la Santé et de la Recherche Médicale, Unité 63, Hôpital de l'Antiquaille, Lyon, France (C.T., F.B.), and The Lipoprotein Group, Department of Biochemistry, Dalhousie University, Halifax, Nova Scotia, Canada (P.J.D.).
Correspondence to Dr Maryse Guérin, INSERM U 321, Pavillion Benjamin Delessert, Hôpital de la Pitié, 83 Boulevard de l'Hôpital, 75651 Paris Cedex 13, France.
Abstract Familial hypercholesterolemia (FH) results from genetic defects in the LDL receptor, and is characterized by a marked elevation in plasma LDL and by qualitative abnormalities in LDL particles. Because LDL particles are major acceptors of cholesteryl esters (CEs) from HDL, significant changes occur in the flux of CE through the reverse cholesterol pathway. To evaluate the effects of an HMG-CoA reductase inhibitor, pravastatin, on CE transfer from HDL to apo B–containing lipoproteins and on plasma lipoprotein subspecies profile in subjects with heterozygous FH, we investigated the transfer of HDL-CE to LDL subfractions and changes in both concentration and chemical composition of the apo B– and the apo AI–containing lipoproteins. After pravastatin treatment (40 mg/d) for a 12-week period, plasma LDL concentrations (mean±SD, 745.4±51.9 mg/dL) were reduced by 36% in patients with FH (n=6). By contrast, the qualitative features of the density profile of LDL subspecies in patients with FH, in whom the intermediate (d=1.029 to 1.039 g/mL) and dense (d=1.039 to 1.063 g/mL) subspecies were significantly increased relative to a control group, were not modified by pravastatin. In addition, no significant effect on the chemical composition of individual LDL subfractions was observed. Furthermore, plasma HDL concentrations were not modified, although the density distribution of HDL was normalized. Indeed, the HDL density peak was shifted towards the HDL2 subfraction (ratios of HDL2 to HDL3 were 0.7 and 1.1 before and after treatment, respectively). Evaluation of plasma CE transfer protein (CETP) mass was performed with an exogenous CE transfer assay. Under these conditions, no modification of plasma CETP protein mass was induced by pravastatin administration. However, the rate of CE transfer from HDL to LDL was reduced by 24% by pravastatin (61±17 µg CE · h-1 · mL-1 plasma; P<.0005), although intermediate and dense LDL subfractions again accounted for the majority (71%) of the total CE transferred to LDL. Thus, pravastatin induced reduction of plasma CETP activity without change in the preferential targeting of the transfer of HDL-CE towards the denser LDL subfractions. In conclusion, pravastatin reduces the elevated flux of CE from HDL to apo B–containing lipoproteins in subjects with heterozygous FH as a result of a reduction in the LDL particle acceptor concentration.
Key Words: LDL particle subspecies • HDL subfractions • HMG-CoA reductase inhibitor • cholesteryl ester
This article has been cited by other articles:
 |
|
 |
|
  H. Nagasaka, T. Miida, K. Hirano, A. Ota, T. Yorifuji, T. Takatani, H. Tsukahara, M. Takayanagi, S.-P. Hui, K. Kobayashi, et al. Reduced Apolipoprotein E-Rich High-Density Lipoprotein Level at Birth Is Restored to the Normal Range in Patients with Familial Hypercholesterolemia in the First Year of Life J. Clin. Endocrinol. Metab., March 1, 2008; 93(3): 779 - 783. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kontush and M. J. Chapman Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis Pharmacol. Rev., September 1, 2006; 58(3): 342 - 374. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Rizzo and K. Berneis Low-density lipoprotein size and cardiovascular risk assessment QJM, January 1, 2006; 99(1): 1 - 14. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Forrester, R. Makkar, and P.K. Shah Increasing High-Density Lipoprotein Cholesterol in Dyslipidemia by Cholesteryl Ester Transfer Protein Inhibition: An Update for Clinicians Circulation, April 12, 2005; 111(14): 1847 - 1854. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Winkler, C. Abletshauser, M. M. Hoffmann, I. Friedrich, M. W. Baumstark, H. Wieland, and W. Marz Effect of Fluvastatin Slow-Release on Low Density Lipoprotein (LDL) Subfractions in Patients with Type 2 Diabetes Mellitus: Baseline LDL Profile Determines Specific Mode of Action J. Clin. Endocrinol. Metab., December 1, 2002; 87(12): 5485 - 5490. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Marz, H. Scharnagl, C. Abletshauser, M. M. Hoffmann, A. Berg, J. Keul, H. Wieland, and M. W. Baumstark Fluvastatin Lowers Atherogenic Dense Low-Density Lipoproteins in Postmenopausal Women With the Atherogenic Lipoprotein Phenotype Circulation, April 17, 2001; 103(15): 1942 - 1948. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Dachet, O. Poirier, F. Cambien, J. Chapman, and M. Rouis New Functional Promoter Polymorphism, CETP/-629, in Cholesteryl Ester Transfer Protein (CETP) Gene Related to CETP Mass and High Density Lipoprotein Cholesterol Levels : Role of Sp1/Sp3 in Transcriptional Regulation Arterioscler. Thromb. Vasc. Biol., February 1, 2000; 20(2): 507 - 515. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Lepage, F. Nigon, D. Bonnefont-Rousselot, U. Assogba, S. Goulinet, L. Chancharme, J. Delattre, E. Bruckert, and M. J. Chapman Oxidizability of Atherogenic Low-Density Lipoprotein Subspecies in Severe Familial Hypercholesterolemia: Impact of Long-Term Low-Density Lipoprotein Apheresis Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 2000; 5(2): 87 - 103. [Abstract] [PDF]
|
|
|
|
|
|
M. Guerin, T. S. Lassel, W. Le Goff, M. Farnier, and M. J. Chapman Action of Atorvastatin in Combined Hyperlipidemia : Preferential Reduction of Cholesteryl Ester Transfer From HDL to VLDL1 Particles Arterioscler. Thromb. Vasc. Biol., January 1, 2000; 20(1): 189 - 197. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. J. Lewis-Barned, W. H. F. Sutherland, R. J. Walker, H. L. Walker, S. A. de Jong, E. A. Edwards, and V. H. Markham Plasma Cholesterol Esterification And Transfer, the Menopause, And Hormone Replacement Therapy in Women J. Clin. Endocrinol. Metab., October 1, 1999; 84(10): 3534 - 3538. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Frénais, K. Ouguerram, C. Maugeais, J. S. Marchini, P. Benlian, J. M. Bard, T. Magot, and M. Krempf Apolipoprotein A-I kinetics in heterozygous familial hypercholesterolemia: a stable isotope study J. Lipid Res., August 1, 1999; 40(8): 1506 - 1511. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. A. Kuivenhoven, J. W. Jukema, A. H. Zwinderman, P. de Knijff, R. McPherson, A. V.G. Bruschke, K. I. Lie, J. J.P. Kastelein, and The Regression Growth Evaluation Statin Study Grou The Role of a Common Variant of the Cholesteryl Ester Transfer Protein Gene in the Progression of Coronary Atherosclerosis N. Engl. J. Med., January 8, 1998; 338(2): 86 - 93. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. S. Lassel, M. Guerin, S. Auboiron, M. J. Chapman, and B. Guy-Grand Preferential Cholesteryl Ester Acceptors Among Triglyceride-Rich Lipoproteins During Alimentary Lipemia in Normolipidemic Subjects Arterioscler. Thromb. Vasc. Biol., January 1, 1998; 18(1): 65 - 74. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Guerin, E. Bruckert, P. J. Dolphin, G. Turpin, and M. J. Chapman Fenofibrate Reduces Plasma Cholesteryl Ester Transfer From HDL to VLDL and Normalizes the Atherogenic, Dense LDL Profile in Combined Hyperlipidemia Arterioscler. Thromb. Vasc. Biol., June 1, 1996; 16(6): 763 - 772. [Abstract] [Full Text]
|
|